



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/721,183	11/22/2000	Susana Salceda	DEX-0117	1493
32800	7590	01/04/2006		
LICATA & TYRRELL P.C. 66 E. MAIN STREET MARLTON, NJ 08053			EXAMINER CANELLA, KAREN A	
			ART UNIT	PAPER NUMBER
			1643	

DATE MAILED: 01/04/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/721,183

Applicant(s)

SALCEDA ET AL.

Examiner

Karen A. Canella

Art Unit

1643

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☐ Claim(s) 3-7 and 18-37 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) 3-7 and 18-37 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. ____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date <u>March 11, 2004</u> | 6) <input checked="" type="checkbox"/> Other: <u>attachment A and B</u> |

DETAILED ACTION

1. After review and reconsideration, the Finality of the previous Office action is withdrawn in light of the rejections below.
2. Claims 3-7 have been amended. Claims 3-7 and 18-37 are pending and under consideration.
3. Text of Title 35, U.S. Code, not found in this action can be found in a prior action.
4. Acknowledgement is made of applicants claim to an earlier effective filing date through application 60/166,973. Upon review of the '973 application it is noted that said application describes the instant SEQ ID NO:1, 2, 4 and 5 but lacks a written description for SEQ ID NO:18. Accordingly, method claims reliant upon the genus of polynucleotides including SEQ ID NO:18 will be given priority only to the instant filing date of November 22, 2000.
5. Claims 3-7 and 18-37 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 3-7 recite the limitation of a polynucleotide which hybridizes under stringent conditions. The recitation of "stringent" conditions does not define the metes and bounds of the physical parameters of the hybridization conditions because "stringent" conditions encompass low, moderate and high stringency. Thus the metes and bounds of the least stringent condition is not defined by the claim and the specification does not provide a definition for stringent hybridization which would set the physical parameters of the hybridization conditions.
6. Claims 3-7 and 18-37 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Art Unit: 1643

The instant method claims are reliant upon the identity of a polynucleotide which hybridizes under undefined conditions to the anti-sense sequence of SEQ ID NO:1, 2, 4, 5 or 18. The specification lacks a definition for "stringent conditions" that would limit the physical parameters of the hybridization, thus the instant claims encompass a genus of polynucleotides which are not limited by sequence similarity to SEQ ID NO:1, 2, 4, 5 or 18. The disclosure of SEQ ID NO:1, 2, 4, 5 and 18 fails to anticipate the claimed genus because the genus tolerates members which differ in structure from SEQ ID NO:1, 2, 4, 5 and 18 and which encode proteins which have a different function from the of the proteins encoded by SEQ ID NO:1, 2, 4, 5 and 18. One of skill in the art would reasonably conclude that applicant was not in possession of the genus of polynucleotides which hybridize to the anti-sense of SEQ ID NO:1, 2, 4, 5 or 18 under any condition of stringency. It logically follows that if applicant was not in possession of the genus of polynucleotides upon which the instant method claims rely, then applicant was not in possession of the instant methods.

7. Claims 3-7 are rejected under 35 U.S.C. 102(e) as being anticipated by Sun et al (US 2003/0175715, priority to October 27, 2000).

Claim 3 is drawn in part to a method for diagnosing the presence of breast cancer in a patient comprising determining the level of a BCSG polynucleotide comprising a polynucleotide which hybridizes under stringent conditions to the anti-sense sequence of SEQ ID NO:4, wherein an increase in the level of said polynucleotide versus a normal human controls is associated with the presence of breast cancer. Claim 4 is drawn in part to a method of diagnosing metastases of breast cancer in a patient and claim 6 is drawn in part to a method of monitoring breast cancer in a patient for the onset of metastasis, both methods comprising identifying a patient having breast cancer that is not known to have metastasized and determining the level of a BCSG polynucleotide in a sample of cells, tissue or bodily fluids from said patient, wherein the BCSG polynucleotide is a polynucleotide which hybridizes under stringent conditions to the anti-sense sequence of SEQ ID NO:4, wherein an increase in the level of said polynucleotide versus a normal human controls is associated with metastatic breast cancer. Claim 5 is drawn in part to a method of staging breast cancer in a patient having breast cancer and claim 7 is drawn in part to a method of monitoring a change in stage of breast cancer in a patient, both methods comprising

Art Unit: 1643

identifying a patient having breast cancer and determining the level of a BCSG polynucleotide levels in a sample of cells, tissue or bodily fluids from said patient, wherein the BCSG polynucleotide is a polynucleotide which hybridizes under stringent conditions to the anti-sense sequence of SEQ ID NO:4, wherein an increase in the level of said polynucleotide versus a normal human controls is associated with breast cancer which is progressing and a decrease is associated with breast cancer which is regressing or in remission.

Sun et al disclose a method of detecting breast cancer, metastasis of breast cancer and a method of staging breast cancer, all methods comprising determining the level of a polynucleotide which hybridizes to a BCG gene. Sun et al disclose that a BCG gene includes SEQ ID NO:35 which would hybridize to the instant SEQ ID NO:4 (paragraphs 0019, 0357, 0364). SEQ ID NO:35 is 99.7% identical to the instant SEQ ID NO:4.

8. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

9. Claim 4 and 6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Jager et al (US 6,774,226) in view of Putnam, ('Metastatic Cancer to the Lung', In: Cancer, Principles and Practice of Oncology, DeVita et al, Eds, 1993, Vol. 2, pp. 2678-2679).

Art Unit: 1643

Claim 4 is drawn in part to a method of diagnosing metastases of breast cancer in a patient and claim 6 is drawn in part to a method of monitoring breast cancer in a patient for the onset of metastasis, both methods comprising identifying a patient having breast cancer that is not known to have metastasized and determining the level of a BCSG polynucleotide in a sample of cells, tissue or bodily fluids from said patient, wherein the BCSG polynucleotide is a polynucleotide which hybridizes under stringent conditions to the anti-sense sequence of SEQ ID NO:5, wherein an increase in the level of said polynucleotide versus a normal human controls is associated with metastatic breast cancer.

Jager et al teach the polynucleotide of SEQ ID NO:15 is present in a breast cancer cDNA library (column 8, lines 9-18). Jager et al teach that 16 of 25 breast cancer samples were strongly positive for SEQ ID NO:15, and 3 additional samples were weakly positive (column 8, lines 38-40). Jager et al teach that expression of SEQ ID NO:15 was not found in normal brain, kidney, liver, colon, adrenal, fetal brain, lung, pancreas, prostate, thymus, uterus, and ovary tissue (column 8, lines 30-32). Jager et al teach that SEQ ID NO:15 was strongly expressed in breast tissue (column 8, lines 28-29, thus Jager et al fails to teach the detection of breast cancer within the breast itself as Jager et al does not provide a contrast in the expression of SEQ ID NO:15 from breast cancer cells versus normal breast cells. However, Jager et al teach a contrast in the expression of SEQ ID NO:15 in breast tumor tissue and normal brain, kidney, liver, colon, adrenal, fetal brain, lung, pancreas, prostate, thymus, uterus, and ovary.

Putnam teaches that breast cancer metastasizes to the bone, lung, brain and liver.

It would have been prima facie obvious at the time the claimed invention was made to detect the polynucleotide of SEQ ID NO:15 in the lung, brain or liver as a means of detecting metastatic breast cancer in lung, brain or liver. One of skill in the art would have been motivated to do so by the teachings of Putnam who identifies these sites for breast metastases and the teachings of Jager et al on the lack of expression of SEQ ID NO:15 in normal brain, liver or lung. SEQ ID NO:15 fulfills the specific embodiment of hybridizing to the instant SEQ ID NO:5 because SEQ ID NO:15 is 93.3% similar to SEQ ID NO:5.

Art Unit: 1643

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen A. Canella whose telephone number is (571)272-0828. The examiner can normally be reached on 11 am to 10 pm, except Wed, Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on (571)272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Karen A. Canella, Ph.D.

12/27/2005


KAREN A. CANELLA PH.D.
PRIMARY EXAMINER

GenCore version 5.1.6
Copyright (c) 1993 - 2005, CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 12, 2005, 09:32:55 ; Search time 2052 Seconds
(without alignments)
2168.876 Million cell updates/sec

Title: US-09-721-183-4
Perfect score: 639
Sequence: 1 ccgaaccagtgtagtcc.....caggaatgacgaggggat 639

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 1.0

Searched: 8443130 seqs, 3482420727 residues
Total number of hits satisfying chosen parameters: 16886260

Minimum DB seq length: 0
Maximum DB seq length: 200000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications NA:
1: /cgn2_6/prodata/1/pubpna/US07_PUBCOMB.seq:
2: /cgn2_6/prodata/1/pubpna/PCT_NEW_PUB.seq:
3: /cgn2_6/prodata/1/pubpna/US06_NEW_PUB.seq:
4: /cgn2_6/prodata/1/pubpna/US06_PUBCOMB.seq:
5: /cgn2_6/prodata/1/pubpna/US07_NEW_PUB.seq:
6: /cgn2_6/prodata/1/pubpna/PCTUS_PUBCOMB.seq:
7: /cgn2_6/prodata/1/pubpna/US08_NEW_PUB.seq:
8: /cgn2_6/prodata/1/pubpna/US08_PUBCOMB.seq:
9: /cgn2_6/prodata/1/pubpna/US09A_PUBCOMB.seq:
10: /cgn2_6/prodata/1/pubpna/US09B_PUBCOMB.seq:
11: /cgn2_6/prodata/1/pubpna/US09C_PUBCOMB.seq:
12: /cgn2_6/prodata/1/pubpna/US09D_PUBCOMB.seq:
13: /cgn2_6/prodata/1/pubpna/US10A_PUBCOMB.seq:
14: /cgn2_6/prodata/1/pubpna/US10B_PUBCOMB.seq:
15: /cgn2_6/prodata/1/pubpna/US10C_PUBCOMB.seq:
16: /cgn2_6/prodata/1/pubpna/US10D_PUBCOMB.seq:
17: /cgn2_6/prodata/1/pubpna/US10E_PUBCOMB.seq:
18: /cgn2_6/prodata/1/pubpna/US10F_PUBCOMB.seq:
19: /cgn2_6/prodata/1/pubpna/US10G_PUBCOMB.seq:
20: /cgn2_6/prodata/1/pubpna/US10H_PUBCOMB.seq:
21: /cgn2_6/prodata/1/pubpna/US10I_PUBCOMB.seq:
22: /cgn2_6/prodata/1/pubpna/US10J_PUBCOMB.seq:
23: /cgn2_6/prodata/1/pubpna/US11A_PUBCOMB.seq:
24: /cgn2_6/prodata/1/pubpna/US11B_PUBCOMB.seq:
25: /cgn2_6/prodata/1/pubpna/US11C_PUBCOMB.seq:
26: /cgn2_6/prodata/1/pubpna/US11D_PUBCOMB.seq:
27: /cgn2_6/prodata/1/pubpna/US11E_PUBCOMB.seq:
28: /cgn2_6/prodata/1/pubpna/US11F_PUBCOMB.seq:
29: /cgn2_6/prodata/1/pubpna/US11G_PUBCOMB.seq:
30: /cgn2_6/prodata/1/pubpna/US11H_PUBCOMB.seq:
31: /cgn2_6/prodata/1/pubpna/US11I_PUBCOMB.seq:
32: /cgn2_6/prodata/1/pubpna/US11J_PUBCOMB.seq:
33: /cgn2_6/prodata/1/pubpna/US11K_PUBCOMB.seq:
34: /cgn2_6/prodata/1/pubpna/US11L_PUBCOMB.seq:
35: /cgn2_6/prodata/1/pubpna/US11M_PUBCOMB.seq:
36: /cgn2_6/prodata/1/pubpna/US11N_PUBCOMB.seq:
37: /cgn2_6/prodata/1/pubpna/US11O_PUBCOMB.seq:
38: /cgn2_6/prodata/1/pubpna/US11P_PUBCOMB.seq:
39: /cgn2_6/prodata/1/pubpna/US11Q_PUBCOMB.seq:
40: /cgn2_6/prodata/1/pubpna/US11R_PUBCOMB.seq:
41: /cgn2_6/prodata/1/pubpna/US11S_PUBCOMB.seq:
42: /cgn2_6/prodata/1/pubpna/US11T_PUBCOMB.seq:
43: /cgn2_6/prodata/1/pubpna/US11U_PUBCOMB.seq:
44: /cgn2_6/prodata/1/pubpna/US11V_PUBCOMB.seq:
45: /cgn2_6/prodata/1/pubpna/US11W_PUBCOMB.seq:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	637.4	99.7	1104	US-10-082-828A-35	Sequence 35, Appl
2	637.4	99.7	1104	US-11-057-807-35	Sequence 35, Appl
3	306	47.9	307	US-10-082-828A-34	Sequence 34, Appl
4	306	47.9	307	US-11-057-807-34	Sequence 34, Appl
5	99.8	15.6	2112	US-10-104-047-1145	Sequence 1145, Ap
6	75.8	11.9	503	US-10-198-846-13943	Sequence 13943, A
7	45.2	7.1	202251	US-10-087-192-985	Sequence 985, App

ATTACHMENT A

C	8	42	6.6	53522	10	US-09-904-968A-1	Sequence 1, Appli
C	9	39.2	6.1	540	19	US-10-021-323-1875	Sequence 1875, Ap
C	10	37.4	5.9	610	13	US-10-027-632-236295	Sequence 236295,
C	11	37.4	5.9	610	13	US-10-027-632-236296	Sequence 236296,
C	12	37.4	5.9	610	13	US-10-027-632-236297	Sequence 236297,
C	13	37.4	5.9	610	13	US-10-027-632-236298	Sequence 236298,
C	14	37.4	5.9	610	13	US-10-027-632-236299	Sequence 236299,
C	15	37.4	5.9	610	17	US-10-027-632-236295	Sequence 236295,
C	16	37.4	5.9	610	17	US-10-027-632-236296	Sequence 236296,
C	17	37.4	5.9	610	17	US-10-027-632-236297	Sequence 236297,
C	18	37.4	5.9	610	17	US-10-027-632-236298	Sequence 236298,
C	19	37.4	5.9	610	17	US-10-027-632-236299	Sequence 236299,
C	20	37.4	5.9	394468	21	US-10-741-600-17952	Sequence 17952, A
C	21	37.4	5.9	418550	17	US-10-292-798-1463	Sequence 1463, Ap
C	22	37.2	5.8	451	18	US-10-424-599-138280	Sequence 138280,
C	23	37.2	5.8	1038	13	US-10-036-729-3	Sequence 3, Appli
C	24	37.2	5.8	2839	18	US-10-425-114-32733	Sequence 32733, A
C	25	37.2	5.8	3134	20	US-10-425-115-119600	Sequence 119600,
C	26	36.6	5.7	195	19	US-10-437-963-28090	Sequence 28090, A
C	27	36.6	5.7	976	19	US-10-437-963-8451	Sequence 8451, Ap
C	28	36.2	5.7	11263	22	US-10-756-149-3787	Sequence 3787, Ap
C	29	36.2	5.7	203132	19	US-10-322-281-459	Sequence 459, App
C	30	36	5.6	1599	18	US-10-425-114-33012	Sequence 33012, A
C	31	36	5.6	1599	20	US-10-425-115-141198	Sequence 141198,
C	32	35.8	5.6	592	13	US-10-027-632-280778	Sequence 280778,
C	33	35.8	5.6	592	17	US-10-027-632-280778	Sequence 280778,
C	34	35.8	5.6	735	13	US-10-027-632-26656	Sequence 26656, A
C	35	35.8	5.6	735	17	US-10-027-632-26656	Sequence 26656, A
C	36	35.8	5.6	401433	22	US-10-737-082-79	Sequence 79, Appl
C	37	35.8	5.6	401433	22	US-10-765-790-79	Sequence 79, Appl
C	38	35.6	5.6	608	20	US-10-425-115-124398	Sequence 124398,
C	39	35.6	5.6	2230	17	US-10-108-260A-1530	Sequence 1530, Ap
C	40	35.6	5.6	7444	15	US-10-128-714-5176	Sequence 5176, Ap
C	41	35.6	5.6	7496	15	US-10-128-714-176	Sequence 176, App
C	42	35.6	5.6	25751	21	US-10-741-600-17722	Sequence 17722, A
C	43	35.6	5.6	38753	19	US-10-741-600-5767	Sequence 5767, Ap
C	44	35.4	5.5	222	18	US-10-424-599-130471	Sequence 130471,
C	45	35.4	5.5	669	18	US-10-424-599-60426	Sequence 60426, A

ALIGNMENTS

RESULT 1

US-10-082-828A-35
; Sequence 35, Application US/10082828A
; Publication No. US20030175715A1
; GENERAL INFORMATION:
; APPLICANT: Sun, Yongming
; APPLICANT: Recipon, Herve
; APPLICANT: Salceda, Sueana
; APPLICANT: Liu, Chenghua
; APPLICANT: Turner, Leah
; TITLE OF INVENTION: Compositions and Methods Relating to Breast Specific Genes and
; FILE REFERENCE: DEX-0247
; CURRENT APPLICATION NUMBER: US/10/082,828A
; CURRENT FILING DATE: 2002-07-09
; PRIOR APPLICATION NUMBER: US 60/243,805
; PRIOR FILING DATE: 2000-10-27
; NUMBER OF SEQ ID NOS: 266
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 35
; LENGTH: 1104
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-082-828A-35

.Query Match 99.7%; Score 637.4; DB 16; Length 1104;
Best Local Similarity 99.8%; Pred. No. 2.4e-194;
Matches 638; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 CCAGAACCGAGTTAGTCCAGGTTCTCGTTCTGCAAAATCTTTCTCTTCTTCTTC 60
|||||

Db	466	CGAGAACGAGTTTAGGTCTCAGGTTCTCGTTCTGGCAAACTTTCTCTCTTACCTTCTTCC	525
Qy	61	TCCACCCCTCCACCTAATGCCATATGTTTTCCTTTAGCCATCCCCAGCTCGGTGAGGAAAG	120
Db	526	TCCACCCCTCCACCTATAGCCATATGTTTTCCTTTAGCCATCCCCAGCTCGGTGAGGAAAG	585
Qy	121	CGAGGCTTAAGTACGTTACCGTCTTCCCGACTTTGCTCAATGATAGCTGGGTGGGTCTAGC	180
Db	586	CGAGGCTTAAGTACGTTACCGTCTTCCCGACTTTGCTCAATGATAGCTGGGTGGGTCTAGC	645
Qy	181	TGGGTTCCAGCCACTTGTAAATGTGGGACATCTCTCACCCCAACTTTTGTAGGTGGAGCAAC	240
Db	646	TGGGTTCCAGCCACTTGTAAATGTGGGACATCTCTCACCCCAACTTTTGTAGGTGGAGCAAC	705
Qy	241	TGCTACAGAGTAATATGATTAATCTTTPACATTCATCTTCGTCTGCTCCCAACTTAA	300
Db	706	TGCTACAGAGTAATATGATTAATCTTTPACATTCATCTTCGTCTGCTCCCAACTTAA	765
Qy	301	CAGCAGGTAACTCGCTTCTACGAGTGGTGAAGCTTAAGAGAGCATCTGTATAGGAGCA	360
Db	766	CAGCAGGTAACTCGCTTCTACGAGTGGTGAAGCTTAAGAGAGCATCTGTATAGGAGCA	825
Qy	361	AGAGATCTGAGTCCTTTTGAAGGCTATCCCTCTGCTCTGTATCTCAATCTGTTCTTCA	420
Db	826	AGAGATCTGAGTCCTTTTGAAGGCTATCCCTCTGCTCTGTATCTCAATCTGTTCTTCA	885
Qy	421	TTTCAAATATCTTACCTATATTCAGTTCCTTTGATCTTTTCTTCTTGGGGCTGTCTT	480
Db	886	TTTGAATATATCTTACCTATATTCAGTTCCTTTGATCTTTTCTTCTTGGGGCTGTCTT	945
Qy	481	AGGTCAGGAGATTTGCAGAGCACCAAGACTAGGAGCAGCCCTGAGACATGGGGAGTTG	540
Db	946	AGGTCAGGAGATTTGCAGAGCACCAAGACTAGGAGCAGCCCTGAGACATGGGGAGTTG	1005
Qy	541	GAGCTGAAGGAGGAATGGCAGGATGAAGAAATTTCCCTAGGTGAGGACGTGTGAGGGTGGCT	600
Db	1006	GAGCTGAAGGAGGAATGGCAGGATGAAGAAATTTCCCTAGGTGAGGACGTGTGAGGGTGGCT	1065
Qy	601	GGGAGAAAGGAGGGGTGGTCACTCAATGGAAGGGGAT	639
Db	1066	GGGAGAAAGGAGGGGTGGTCACTCAATGGAAGGGGAT	1104

RESULT 2
 US-11-057-807-35
 ; Sequence 35, Application US/11057807
 ; Publication No. US20050136473A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Sun, Yongming
 ; APPLICANT: Recipon, Herve
 ; APPLICANT: Salceda, Susana
 ; APPLICANT: Liu, Chenghua
 ; APPLICANT: Turner, Leah
 ; TITLE OF INVENTION: Compositions and Methods Relating to Breast Specific Genes and PR
 ; FILE REFERENCE: DEX-0247
 ; CURRENT APPLICATION NUMBER: US/11/057,807
 ; CURRENT FILING DATE: 2005-02-14
 ; PRIOR APPLICATION NUMBER: US/10/082,828
 ; PRIOR FILING DATE: 2002-07-09
 ; PRIOR APPLICATION NUMBER: US 60/243,805
 ; PRIOR FILING DATE: 2000-10-27
 ; NUMBER OF SEQ ID NOS: 266
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 35
 ; LENGTH: 1104
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-11-057-807-35

Query Match	99.7%	Score 637.4;	DB 24;	Length 1104;
Best Local Similarity	99.8%	Pred. No. 2.4e-194;		
Matches 638; Conservative	0;	Mismatches 1;	Indels 0;	Gaps 0;

Qy	1	CCAGAACCGAGTTTAGTCTCAGGTTCTCGTTCCTGGCAAAATCTTTCTCCTTACCTTCTTCC	60
Db	466	CCAGAACCGAGTTTAGTCTCAGGTTCTCGTTCCTGGCAAAATCTTTCTCCTTACCTTCTTCC	525
Qy	61	TCACACCCCTCCACCTATGCCATGTTTTCCCTTAGCCACTCCCCAGCTCGGTGAGGAAAG	120
Db	526	TCACACCCCTCCACCTATGCCATGTTTTCCCTTAGCCACTCCCCAGCTCGGTGAGGAAAG	585
Qy	121	GCAGGCCCTAACTAGGTACCGTCTTCCCGACTTTTGGCTCAATGATAGCTGGGTGGGTCTAGC	180
Db	586	GCAGGCCCTAACTAGGTACCGTCTTCCCGACTTTTGGCTCAATGATAGCTGGGTGGGTCTAGC	645
Qy	181	TGGGTTCCAGCCCACTTGTAAATGTGGGACATCTCTCACCCCACTTTGTAGGTGGAGCAAC	240
Db	646	TGGGTTCCAGCCCACTTGTAAATGTGGGACATCTCTCACCCCACTTTGTAGGTGGAGCAAC	705
Qy	241	TGCTACAGAGGTAAATATGATTAATCATTTCCATCTTTTGGCTGTCTGCCAAACTTTAA	300
Db	706	TGCTACAGAGGTAAATATGATTAATCATTTCCATCTTTGGCTGTCTGCCAAACTTTAA	765
Qy	301	CAGCAGGTAACTGCTTTCTAGCAAGTGGTGAAGGTAAAGAGCACTCTGTATAGGAGCA	360
Db	766	CAGCAGGTAACTGCTTTCTAGCAAGTGGTGAAGGTAAAGAGCACTCTGTATAGGAGCA	825
Qy	361	AGAGATCTGAGTCCTTTTGAAGGCCCTATCCTCGCTCTGTACTCTCAATTACTGTTCTTCA	420
Db	826	AGAGATCTGAGTCCTTTTGAAGGCCCTATCCTCGCTCTGTACTCTCAATTACTGTTCTTCA	885
Qy	421	TTTCAATTAATTCCTACTACTATTCAGTTCCCTTGATCTTTTCTCTGGGGGCTGTCTT	480
Db	886	TTTGAATTAATTCCTACTACTATTCAGTTCCCTTGATCTTTTCTCTGGGGGCTGTCTT	945
Qy	481	AGGGTCAGGAGATTTCAGAGCACACAGAACTTAGAGAGCCCTTGAGACATGCGGAGTTG	540
Db	946	AGGGTCAGGAGATTTCAGAGCACACAGAACTTAGAGAGCCCTTGAGACATGCGGAGTTG	1005
Qy	541	GAGCTCAAGGAGGAATGGCAGGATGAAGAAATCCCTTAGGTAGGACGCTGTGAGGGTGGCT	600
Db	1006	GAGCTCAAGGAGGAATGGCAGGATGAAGAAATCCCTTAGGTAGGACGCTGTGAGGGTGGCT	1065
Qy	601	GGGAGAGGGAGGGGTGGTCAACGAATGGACGAGGGGAT	639
Db	1066	GGGAGAGGGAGGGGTGGTCAACGAATGGACGAGGGGAT	1104

RESULT 3

RESULT 3
 US-10-082-828A-34
 ; Sequence 34, Application US/10082828A
 ; Publication No. US20030175715A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Sun, Yongming
 ; APPLICANT: Recipon, Herve
 ; APPLICANT: Salceda, Susana
 ; APPLICANT: Liu, Chenghua
 ; APPLICANT: Turner, Leah
 ; TITLE OF INVENTION: Compositions and Methods Relating to Breast Specific Genes and

```

; TYPE: DNA
; ORGANISM: Homo sapiens
US-11-057-807-35

```

Query Match 99.7%; Score 637.4; DB 24; Length 1104;
Best Local Similarity 99.8%; Pred. No. 2.4e-194;
Matches 638; Conservative 0; Mismatches 1; Indels 0;

ATTACHMENT B

GenCore version 5.1.6
Copyright (c) 1993 - 2005, Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 14, 2005, 20:43:00 ; Search time 191 Seconds

(without alignments)
6673.610 Million cell updates/sec

Title: US-09-721-183-5

Perfect score: 779

Sequence: 1 gatacatctttattatc.....gaaactgtcagaagcaaaaa 779

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 1202784 seqs, 818138359 residues

Total number of hits satisfying chosen parameters: 2405568

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Issued Patents NA: *
1: /cgn2_6/prodata/1/ina/5A_COMB.seq.*
2: /cgn2_6/prodata/1/ina/5B_COMB.seq.*
3: /cgn2_6/prodata/1/ina/6A_COMB.seq.*
4: /cgn2_6/prodata/1/ina/6B_COMB.seq.*
5: /cgn2_6/prodata/1/ina/PCUTUS_COMB.seq.*
6: /cgn2_6/prodata/1/ina/backfileseq1.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	727	93.3	2030	4	US-09-451-739H-15
2	725.8	93.2	2232	4	US-09-620-405B-491
3	725.8	93.2	2232	4	US-09-834-759-491
4	725.8	93.2	3288	4	US-09-620-405B-490
5	725.8	93.2	3288	4	US-09-834-759-490
6	725.8	93.2	3681	4	US-09-433-826B-463
7	725.8	93.2	3681	4	US-09-604-287A-463
8	725.8	93.2	3681	4	US-09-834-759-463
9	725.8	93.2	3681	4	US-09-590-751A-463
10	725.8	93.2	3681	4	US-09-551-621-463
11	725.8	93.2	3681	4	US-09-620-405B-474
12	725.8	93.2	3865	4	US-09-604-287A-474
13	725.8	93.2	3865	4	US-09-834-759-474
14	725.8	93.2	3865	4	US-09-590-751A-474
15	725.8	93.2	3865	4	US-09-551-621-474
16	725.8	93.2	3865	4	US-09-620-405B-467
17	723.8	92.9	1337	4	US-09-433-826B-467
18	723.8	92.9	1337	4	US-09-604-287A-467
19	723.8	92.9	1337	4	US-09-834-759-467
20	723.8	92.9	1337	4	US-09-590-751A-467
21	723.8	92.9	1337	4	US-09-551-621-467
22	723.8	92.9	2307	4	US-09-620-405B-468
23	723.8	92.9	2307	4	US-09-433-826B-468
24	723.8	92.9	2307	4	US-09-604-287A-468
25	723.8	92.9	2307	4	US-09-834-759-468
26	723.8	92.9	2307	4	US-09-590-751A-468
27	723.8	92.9	2307	4	US-09-551-621-468

28	723.8	92.9	2307	4	US-09-551-621-468	Sequence 468, App
29	547.2	70.2	1729	4	US-09-620-405B-466	Sequence 466, App
30	547.2	70.2	1729	4	US-09-433-826B-466	Sequence 466, App
31	547.2	70.2	1729	4	US-09-604-287A-466	Sequence 466, App
32	547.2	70.2	1729	4	US-09-834-759-466	Sequence 466, App
33	547.2	70.2	1729	4	US-09-590-751A-466	Sequence 466, App
34	547.2	70.2	1729	4	US-09-551-621-466	Sequence 466, App
35	414.6	53.2	1665	4	US-09-389-681-178	Sequence 178, App
36	414.6	53.2	1665	4	US-09-620-405B-178	Sequence 178, App
37	414.6	53.2	1665	4	US-09-339-338-178	Sequence 178, App
38	414.6	53.2	1665	4	US-09-433-826B-178	Sequence 178, App
39	414.6	53.2	1665	4	US-09-604-287A-178	Sequence 178, App
40	414.6	53.2	1665	4	US-09-834-759-178	Sequence 178, App
41	414.6	53.2	1665	4	US-09-590-751A-178	Sequence 178, App
42	414.6	53.2	1665	4	US-09-551-621-178	Sequence 178, App
43	414.6	30.4	1424	4	US-09-620-405B-464	Sequence 464, App
44	236.6	30.4	1424	4	US-09-433-826B-464	Sequence 464, App
45	236.6	30.4	1424	4	US-09-620-405B-464	Sequence 464, App

ALIGNMENTS

RESULT 1

US-09-451-739H-15

; Sequence 15, Application US/09451739H

; Patent No. 6774226

; GENERAL INFORMATION:

; APPLICANT: Jager, Dirk

; APPLICANT: Scanlan, Matthew

; APPLICANT: Gure, Ali

; APPLICANT: Jager, Elke

; APPLICANT: Knuth, Alexander

; APPLICANT: Old, Lloyd

; APPLICANT: Chen, Yao-tseng

; TITLE OF INVENTION: Isolated Nucleic Acid Molecules Encoding Cancer Associated Anti-

; TITLE OF INVENTION: the Antigens per se, and Uses Thereof

; FILE REFERENCE: LUD 5615

; CURRENT APPLICATION NUMBER: US/09/451,739H

; CURRENT FILING DATE: 1999-11-30

; NUMBER OF SEQ ID NOS: 19

; SEQ ID NO 15

; LENGTH: 2030

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: CDS

; LOCATION: 1628, 1752, 1758, 1769, 1789, 1873, 1908, 1915, 1933, 1970,

; LOCATION: 1976, 2022

; OTHER INFORMATION: unknown nucleotides at positions 1628, 1752, 1758,

; OTHER INFORMATION: 1769, 1789, 1873, 1908, 1915, 1933, 1970, 1976, 2022

US-09-451-739H-15

Query Match

Best Local Similarity 93.3%; Score 727; DB 4; Length 2030;

Matches 733; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 36 CCATTAGCCTCCATTGAAATGCAAAAGCTGTGTTCCAAATAAAGCCTTGGAAATGAAGA 95

Db 124 CTTTCGAGCCTCCATTGAAATGCAAAAGCTGTGTTCCAAATAAAGCCTTGGAAATGAAGA 183

QY 96 ATGAACAACATTTGAGAGCAGATGAGATGATCTCCCATCAGATCCCAACAAGAGGACTATG 155

Db 184 ATGAACAACATTTGAGAGCAGATGAGATGATCTCCCATCAGATCCCAACAAGAGGACTATG 243

QY 156 AAGAAGTTCTTGGGATTTCTGAGAGTCTCTGTGAGAGTCTTTTACAGAGAGGATGTGTGT 215

Db 244 AAGAAGTTCTTGGGATTTCTGAGAGTCTCTGTGAGAGTCTTTTACAGAGAGGATGTGTGT 303

QY 216 TACCCAAAGGCTACATCAATCAAAAGAAATAGATAAAATAAATGAAATTTAGAGGCTCTC 275

Db 304 TACCCAAAGGCTACATCAATCAAAAGAAATAGATAAAATAAATGAAATTTAGAGGCTCTC 363

```
QY 276 CTGTTAAAGTGTCTCTCTGAGGCTAACTGCGGATGAAGTTTCTATTCCAACTAAAG 335
DB 364 CTGATAATGATGTTTCTGGAAGGCTCCCTGCGAATGAAGTTTCTATTCCAACTAAAG 423
QY 336 CCTTAGAATTGATGGACATGCAAACTTTCAAAGCAGAGCCTCCCGAGAGCCATCTGCCT 395
DB 424 CCTTAGAATTGATGGACATGCAAACTTTCAAAGCAGAGCCTCCCGAGAGCCATCTGCCT 483
QY 396 TCAGAGCTGCATGTAAATGCAAAAGTCTGTTCCAAATAAAGCCTTGGAAATGGAAGATG 455
DB 484 TCAGAGCTGCATGTAAATGCAAAAGTCTGTTCCAAATAAAGCCTTGGAAATGGAAGATG 543
QY 456 AACAAACATTGAGAGCAGATCAGATGTTCCCTTCAAGATCAAAACAAAGAGGTTGAAG 515
DB 544 AACAAACATTGAGAGCAGATCAGATGTTCCCTTCAAGATCAAAACAAAGAGGTTGAAG 603
QY 516 AAAATTTCTGGGATTTCTGAGAGTCTCCGTGAGACTGTTTCAAGAAAGGATGTGTGTAC 575
DB 604 AAAATTTCTGGGATTTCTGAGAGTCTCCGTGAGACTGTTTCAAGAAAGGATGTGTGTAC 663
QY 576 CCAAGGCTACATCAAAAGAAATGGAATAAATAGTGGAATTTAGAAATTCAACTA 635
DB 664 CCAAGGCTACATCAAAAGAAATGGAATAAATAGTGGAATTTAGAAATTCAACTA 723
QY 636 GCTATCAAAATCTTGATACAGTTCATTTCTGTAAGAGCAAGGAACTTCAAAAG 695
DB 724 GCTATCAAAATCTTGATACAGTTCATTTCTGTAAGAGCAAGGAACTTCAAAAG 783
QY 696 ATCACTGTGAACAACTGACAGGAAATGGAATAAATGGAATAAATGGAATAAATGGAATAA 755
DB 784 ATCACTGTGAACAACTGACAGGAAATGGAATAAATGGAATAAATGGAATAAATGGAATAA 843
QY 756 AAAAGAACTGTGAGAGCAAAA 778
DB 844 AAAAGAACTGTGAGAGCAAAA 866
```

RESULT 2

US-09-620-405B-491
; Sequence 491, Application US/09620405B
; Patent No. 6528054

GENERAL INFORMATION:
; APPLICANT: Jiang, Yugui

; APPLICANT: Dillon, Davin C.
; APPLICANT: Mitcham, Jennifer L.

; APPLICANT: Xu, Jiangchun
; APPLICANT: Harlocker, Susan L.

; APPLICANT: Hepler, William T.
; APPLICANT: Henderson, Robert A.

TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY AND
DIAGNOSIS OF BREAST CANCER

FILE REFERENCE: 210121.470C8

CURRENT APPLICATION NUMBER: US/09/620.405B

CURRENT FILING DATE: 2000-07-20

NUMBER OF SEQ ID NOS: 495

SOFTWARE: FastSeq for Windows Version 3.0

SEQ ID NO 491

LENGTH: 2232

TYPE: DNA

ORGANISM: Homo sapiens

US-09-620-405B-491

Query Match 93.2%; Score 725.8; DB 4; Length 2232;
Best Local Similarity 98.3%; Pred. No. 2.8e-185;
Matches 730; Conservative 3; Mismatches 10; Indels 0; Gaps 0;

```
QY 36 CCATTTAGCTGCCATTCGAATGCAAAAGTCTGTTCCAAATAAAGCCTTGGAAATGAAGA 95
DB 1373 CCTTCGAGCTGCCATTCGAATGCAAAAGTCTGTTCCAAATAAAGCCTTGGAAATGAAGA 1432
```

```
QY 96 ATGAACAAACATTGAGAGCAGATGAGATCTCCCATCAGAAATCCAAACAAAGACTATG 155
DB 1433 ATGAACAAACATTGAGAGCAGATGAGATCTCCCATCAGAAATCCAAACAAAGACTATG 1492
```

```
QY 156 AAGAAAGTTCTGGATTTCTGAGATCTCTGAGACTGTTTCAAGAAAGGATGTGTGT 215
DB 1493 AAGAAAGTTCTGGATTTCTGAGATCTCTGAGACTGTTTCAAGAAAGGATGTGTGT 1552
QY 216 TACCCAGGCTACACATCAAAAGAAATAGATAAATAAATGGAATAAATAGAAAGGTTCTC 275
DB 1553 TACCCAGGCTACACATCAAAAGAAATAGATAAATAAATGGAATAAATAGAAAGGTTCTC 1612
QY 276 CTGTTAAAGTGTCTCTGAGAGCTTAAGTGGGATGAAGTTTCTATTCCAACTAAAG 335
DB 1613 CTGTTAAAGTGTCTCTGAGAGCTTAAGTGGGATGAAGTTTCTATTCCAACTAAAG 1672
QY 336 CCTTAGAATTGATGACATGCAAACTTTCAAAGCAGAGCCTCCCGAGAGCCATCTGCCT 395
DB 1673 CCTTAGAATTGATGACATGCAAACTTTCAAAGCAGAGCCTCCCGAGAGCCATCTGCCT 1732
QY 396 TCAGAGCTGCCATTCGAATGCAAAAGTCTGTTCCAAATAAAGCCTTGGAAATGGAAGATG 455
DB 1733 TCAGAGCTGCCATTCGAATGCAAAAGTCTGTTCCAAATAAAGCCTTGGAAATGGAAGATG 1792
QY 456 AACAAACATTGAGAGCAGATCAGATGTTCCCTTCAAGATCAAAACAAAGAGGTTGAAG 515
DB 1793 AACAAACATTGAGAGCAGATCAGATGTTCCCTTCAAGATCAAAACAAAGAGGTTGAAG 1852
QY 516 AAAATTTCTGGGATTTCTGAGAGTCTCCGTGAGACTGTTTCAAGAAAGGATGTGTGTAC 575
DB 1853 AAAATTTCTGGGATTTCTGAGAGTCTCCGTGAGACTGTTTCAAGAAAGGATGTGTGTAC 1912
QY 576 CCAAGGCTACATCAAAAGAAATGGAATAAATAGTGGAATAAATAGTGGAATAAATAGTGGA 635
DB 1913 CCAAGGCTACATCAAAAGAAATGGAATAAATAGTGGAATAAATAGTGGAATAAATAGTGGA 1972
QY 636 GCTATCAAAATCTTGATACAGTTCATTTCTGTAAGAGCAAGGAACTTCAAAAG 695
DB 1973 GCTATCAAAATCTTGATACAGTTCATTTCTGTAAGAGCAAGGAACTTCAAAAG 2032
QY 696 ATCACTGTGAACAACTGACAGGAAATGGAATAAATGGAATAAATGGAATAAATGGAATAA 755
DB 2033 ATCACTGTGAACAACTGACAGGAAATGGAATAAATGGAATAAATGGAATAAATGGAATAA 2092
QY 756 AAAAGAACTGTGAGAGCAAAA 778
DB 2093 AAAAGAACTGTGAGAGCAAAA 2115
```

RESULT 3

US-09-834-759-491

; Sequence 491, Application US/09834759

; Patent No. 6680197

GENERAL INFORMATION:

; APPLICANT: Jiang, Yugui

; APPLICANT: Dillon, Davin C.

; APPLICANT: Mitcham, Jennifer L.

; APPLICANT: Xu, Jiangchun

; APPLICANT: Harlocker, Susan L.

; APPLICANT: Hepler, William T.

; APPLICANT: Henderson, Robert A.

TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY AND

DIAGNOSIS OF BREAST CANCER

FILE REFERENCE: 210121.470C9

CURRENT APPLICATION NUMBER: US/09/834.759

CURRENT FILING DATE: 2001-04-13

NUMBER OF SEQ ID NOS: 547

SOFTWARE: FastSeq for Windows Version 3.0

SEQ ID NO 491

LENGTH: 2232

TYPE: DNA

ORGANISM: Homo sapiens

US-09-834-759-491

Query Match 93.2%; Score 725.8; DB 4; Length 2232;
Best Local Similarity 98.3%; Pred. No. 2.8e-185;
Matches 730; Conservative 3; Mismatches 10; Indels 0; Gaps 0;